Seasoned industry executives add expertise ahead of anticipated continued corporate growth

BOSTON , Jan. 19, 2023 /PRNewswire/ — Ace Vision Team, Inc, (AVG) an emerging ophthalmic device company focused on bringing innovative touchless lasers in order to patients suffering from age-related vision loss and eye diseases impacted by ocular rigidity, announced multiple executive appointments today.   John Frantzis will serve as Chief Business Development Officer plus Alex Lopez will serve as Chief Commercial Officer effective January 19, 2023 .

“Our team is ecstatic to have such notable in addition to experienced strategic leaders in the ophthalmic industry joining Ace Eyesight Group at this stage of the company’s journey, ” said AnnMarie Hipsley , DPT, Ph. D., Founder and even CEO associated with AVG. “I have great respect for the accomplishments of both Mr. Steve Frantzis together with Mr. Alex Lopez inside each regarding their longstanding careers in healthcare. I am eager to see their impact on AVG’s commercial strategy and additionally success. Building an impeccable executive leadership involving C-level talent will contribute immeasurably to be able to AVG’s continual growth toward commercialization connected with our flagship technology, the particular VisioLite® Ophthalmic Laser System and typically the Laser Scleral Microporation (LSM) procedure. LSM will be the first medical gadget for the therapeutic treatment of this progressive loss of Dynamic Range with Focus (DRoF) which occurs with age and manifests as presbyopia.

As Main Business Growth Officer, Frantzis will lead AVG ‘s strategic venture capital funding efforts, global business development, distribution, not to mention sales. Frantzis has more than 25 years for executive management experience within emerging technologies with experience in producing high development and results driven products in often the biotech and also pharma spaces. Frantzis was a key member about management that pioneered laser vision correction surgery leading Summit Technology, Inc. into commercialization, which was later acquired for nearly $1 billion by Alcon. Frantzis also formerly served on your executive administration team at Avedro, which usually was acquired by Glaukos in 2020 for $380 million . Most recently, Frantzis worked with Heru ( Bascom Palmer innovation), where he secured $30 million in a Series A financing round led simply by D1 Capital.  

“The VisioLite Ophthalmic Laser System is the most innovative technology I have seen in the last 20 years. LSM therapy has the potential to have a significant impact on the exact presbyopia market, which is the largest market opportunity inside ophthalmology with limited available treatment options, ” stated AVG Key Business Enhancement Officer, Frantzis. “I am honored for you to be part of the AVG team and play a role in introducing a revolutionary therapy this kind of as LSM into the particular ophthalmic marketplace. ”

Lopez brings more than two decades of experience in typically the eye care industry to help AVG. In his new role as Chief Industrial Officer, Lopez will be responsible for this commercial launch of AVG’s technology platform, the VisioLite Laser as well as the LSM therapeutic procedure. Previously, Lopez served because Chief Business Officer with regard to Legrande Health, an innovative online healthcare commerce system. Lopez has been also former acting President of The Aliso Group, a healthcare and consumer consulting firm, and has successfully commercialized several products from inception to market. Lopez brings extensive marketing, sales and branding expertise in the elective process market gained during his successful 22-year career. Lopez’s unique hybrid experience in both ophthalmic therapeutics at Allergan and aesthetics at Healthegy AIS gives him the perfect unique combination of expertise in order to launch AVG’s therapeutic program. Lopez was key found in determining AVG’s strategic reccurring revenue models for LSM, which like cosmetic injectables, is a solution to rejuvenate the effects of a progressive aging disease.

“I am excited to be working with such an inventive group and bringing innovative technologies to market that will has the potential to change the presbyopia standard in care. This is the great opportunity to create a new recurring revenue category for ophthalmologists, while providing patients with a higher level of care with often the first in-office therapeutic treatment for the presbyopic patient, ” said Lopez, newly appointed Chief Professional Officer from AVG. “My longstanding experience in ophthalmology combined with my experience in aesthetics is perfectly suited to support the corporate and commercial vision of AVG. inch

About Laser Scleral Microporation (LSM)

Advanced Glycation End Products (AGEs) contribute to age-related connective tissue damage, functional deficits, crosslinking of collagens and your progressive stiffening of connective tissues throughout the body. Ocular solidity caused by progressive crosslinking and scleral stiffness has been linked to the exact etiology associated with the progressive loss regarding Dynamic Range of Focus (DRoF), characteristically known since ‘presbyopia’. LSM is a new minimally invasive laser treatment aimed at rejuvenating the age-related ocular stiffness brought on by AGEs. It works by simply uncrosslinking scleral bonds plus decreasing ocular stiffness to be able to restore DRoF. This allows the natural dynamic movements of the ciliary muscles that shape the crystalline lens inside of the eye to move again. LSM will be a dosable, re-treatable solution for the particular ever-progressive problem of crosslinking and age-related vision reduction which can be utilized throughout the lifecycle of a pre-cataract presbyope.   LSM therapy is performed with typically the VisioLite® touchless laser technological innovation and is this first biomechanical solution for you to address often the underlying biomechanical problems lurking behind your progressive loss of DRoF. Early studies have demonstrated that there may end up being potential visual health benefits in restoring the exact DRoF function in the eye.

About Gen II VisioLite® Ophthalmic Laser System

The VisioLite® Ophthalmic Laser beam System is a new first in class 2. 94um Er: Yag laser that contains a patented robotic motion controller in addition to eye tracker which allows the device to reach 360-degrees of the extreme areas around the particular eye. The particular in-line OCT has the capability to perform real-time adaptive depth control for typically the utmost safety. VisioLite is designed having a robust software module to allow the Microporation pattern to be customized and even repeated. The procedure is performed in-office and takes less than 10 minutes. LSM is a touchless, painless remedy that rejuvenates the sclera without touching any optical elements of this eye. The procedure results are noticeable on the same or next day.   AVG is currently preparing regarding the commercialization of its Style II VisioLite® Ophthalmic Laserlight System around 2023.

About Ace Vision Team

Established in 2006, Expert Vision Class, Inc. (AVG) is a privately held U. S. ophthalmic medical system company developing Laser Microporation Therapeutic systems to address age-related vision dysfunction together with restore often the eye’s organic biomechanical performance.   AVG’s Laser Scleral Microporation (LSM) is the only therapeutic eye laser treatment that restores visual function naturally without involving vision correction, artificial implants, or devices. AVG’s brand promise is to provide your field involving ophthalmology along with innovative products, Microporation Therapeutic procedures, and additionally education intended for the therapy and delay of onset of age-related ocular dysfunction, disability, and disease. For a lot more information about Ace Perspective Group please visit www.acevisiongroup.com.

Media Contact:
Cassandra Dump
[email protected]  
619-971-1887

Organization Contact:
Emily Zimcosky
[email protected]    
330-807-1929

SOURCE Ace Eye-sight

Leave a Reply

Your email address will not be published. Required fields are marked *